This review presents the current state of the art regarding multiparametric magnetic resonance (MR) imaging of prostate cancer. Technical requirements and clinical indications for the use of multiparametric MR imaging in detection, localization, characterization, staging, biopsy guidance, and active surveillance of prostate cancer are discussed. Although reported accuracies of the separate and combined multiparametric MR imaging techniques vary for diverse clinical prostate cancer indications, multiparametric MR imaging of the prostate has shown promising results and may be of additional value in prostate cancer localization and local staging. Consensus on which technical approaches (field strengths, sequences, use of an endorectal coil) and combination of multiparametric MR imaging techniques should be used for specific clinical indications remains a challenge. Because guidelines are currently lacking, suggestions for a general minimal protocol for multiparametric MR imaging of the prostate based on the literature and the authors’ experience are presented. Computer programs that allow evaluation of the various components of a multiparametric MR imaging examination in one view should be developed. In this way, an integrated interpretation of anatomic and functional MR imaging techniques in a multiparametric MR imaging examination is possible. Education and experience of specialist radiologists are essential for correct interpretation of multiparametric prostate MR imaging findings. Supportive techniques, such as computer-aided diagnosis are needed to obtain a fast, cost-effective, easy, and more reproducible prostate cancer diagnosis out of more and more complex multiparametric MR imaging data.

From the Departments of Radiology (C.M.A.H., J.O.B., T.H., D.Y., S.W.T.P.J.H., T.W.J.S., P.C.V., H.Y., A.H., J.J.F.) and Urology (D.M.S., I.M.v.O., J.A.W.), Radboud University Nijmegen Medical Centre, Geert Grooteplein zuid 10, NL 6500 HB, Nijmegen, the Netherlands; and Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands (D.M.S.). Received October 14, 2009; revision requested December 16; revision received July 5, 2010; accepted August 27; final version accepted January 14, 2011; final review by C.M.A.H June 1. Supported by the Dutch Cancer Society. Address correspondence to C.M.A.H. (e-mail: C.Hoeks@rad.umcn.nl).

© RSNA, 2011
The most recent estimation by the International Agency for Research on Cancer revealed 679,000 new cases of and 221,000 deaths related to prostate cancer on a global level in 2002 (1). With an estimated 5-year prevalence of 2.3 million patients in the world, prostate cancer is a major global health problem.

Prostate cancer diagnostics are initiated on the basis of prostate-specific antigen (PSA) measurements and determination of clinical stage by means of digital rectal examination. Definite diagnosis is usually obtained by means of transrectal ultrasonography (US)-guided systematic random prostate biopsies. Histopathologic analysis of these biopsy samples provides the clinician with information on the Gleason score. This is a histopathologic score that correlates with prostate cancer prognosis (2,3).

Nomograms (4) based on the combination of PSA level, digital rectal examination findings, and systematic random biopsy–based Gleason score are used to determine the choice of therapy and prognosis. However, each of these tests has its shortcomings: Digital rectal examination has a low overall sensitivity (37%) and low positive predictive value when lower PSA ranges of 0–3 ng/mL are encountered (5). PSA measurement has yielded higher detection rates than has digital rectal examination (6), but its specificity is low (36%) owing to false-positive PSA elevation under benign circumstances, such as inflammation or benign prostatic hyperplasia (BPH) (7). When digital rectal examination results are positive or when the PSA level is elevated, systematic random sextant biopsy with acquisition of a minimum of four extra cores from lateral peripheral zones or from a region that is suspicious for cancer is generally recommended to be performed initially (8). Systematic random biopsy is prone to undersampling (35% cancers missed on first biopsy [9] and underestimation Gleason grade in 46% of cases [10]). These inaccurate tools often lead to incorrect diagnoses, inaccurate risk assessments, and less optimal therapy choices. Because these diagnostic methods all have their limitations, there is a need for improved prostate cancer diagnosis with improved detection, localization, and sampling.

In the mid 1980s, the first prostate magnetic resonance (MR) imaging examinations were performed. Since then, MR imaging has evolved from a promising technique into a mature prostate imaging modality (11,12). MR imaging can provide functional tissue information along with anatomic information. To increase the accuracy, anatomic T2-weighted MR imaging and functional MR imaging techniques such as dynamic contrast agent–enhanced MR imaging, diffusion-weighted (DW) imaging, and hydrogen 1 MR spectroscopic imaging should be combined in an integrated multiparametric MR imaging examination. These multiparametric MR techniques will contribute to prostate cancer diagnostics, although results for detection, localization, and local staging of prostate cancer vary greatly among the studies performed.

This article will describe the fundamentals of multiparametric MR imaging of prostate cancer. We will provide an overview of the individual MR imaging techniques with their combined merits and limitations for clinical challenges such as detection, localization, local staging, and active surveillance of prostate cancer.

MR Imaging Techniques

Anatomic T2-weighted MR Imaging

T2-weighted MR imaging is the workhorse of prostate MR imaging. T2-weighted MR images have high spatial resolution and, thus, can clearly differentiate the normal intermediate- to high-signal-intensity peripheral zone from the low-signal-intensity central and transition zones in young male subjects (13). In the aging man, owing to variable extension of the transition zone due to BPH, the size and signal intensity

Published online
10.1148/radiol.11091822

Radiology 2011; 261:46–66

Abbreviations:
ADC = apparent diffusion coefficient
AUC = area under the receiver operating characteristic curve
BPH = benign prostatic hyperplasia
DW = diffusion weighted
Ktrans = volume transfer constant
PSA = prostate-specific antigen

Potential conflicts of interest are listed at the end of this article.
of the prostate transition zone may vary. BPH itself is a round, well-defined, inhomogeneous area with (variable) intermediate signal intensity and a low-signal-intensity rim that surrounds the expanded transition zone (12). Because of transition zone expansion, the remainder of the compressed central zone is often indefinable on MR images.

High-spatial-resolution T2-weighted rapid acquisition with refocused echo sequences with a small field of view, performed with endorectal and/or external body phased-array coils, are generally used to depict prostate anatomy. T1-weighted contrast in the prostate is very low. Therefore, it is not possible to appreciate the different anatomic zones on T1-weighted images. On T2-weighted images, prostate cancer can appear as an area of low signal intensity within the high signal intensity of a normal peripheral zone. An example of this finding is shown in Figure 1a. The degree of signal intensity decrease may differ with the Gleason score: Higher Gleason score components 4 or 5 have shown lower signal intensities than do lower Gleason score components 2 and 3 (14). The density and the growth pattern of the cancer may also influence T2-weighted signal intensity. Cancers in the peripheral zone, which grow thinly scattered into the surrounding normal tissue, have shown no significant difference in quantitative T2 values with normal peripheral zone. On the other hand, densely growing cancers do show lower quantitative T2 values (15).

A limitation of T2-weighted imaging is that focal areas of low signal intensity in the peripheral zone do not always represent cancer. Benign abnormalities such as chronic prostatitis, atrophy, scars, postirradiation or hormonal treatment effects, hyperplasia, and postbiopsy hemorrhage may mimic tumor tissue (16). Low-signal-intensity lesions with a wedge shape and a diffuse extension without mass may be reliable signs of benignity (17). Hemorrhage may be differentiated on the basis of its high signal intensity on T1-weighted images. When methemoglobin is present in hemorrhagic regions, its paramagnetic characteristics result in high signal intensity on T1-weighted MR images. Preferably, MR imaging of patients suspected of having prostate cancer should be avoided for 8 weeks after prostate biopsy to allow reduction of artifacts due to postbiopsy hemorrhage (18).

Owing to the presence of BPH, cancer in central and transition zones is more difficult to discern. BPH may have signal intensity similar to that of prostate cancer on T2-weighted images. However, it has been reported that features such as homogeneously low T2-weighted signal intensity (Fig 1b), ill-defined irregular edges of the suspicious lesion, invasion into the urethra or the anterior fibromuscular stroma (Fig 1b), and lenticular shape are helpful signs for detection of malignancy in the transition zone (19).

Combined T1-weighted and T2-weighted MR imaging should be used for all clinical prostate cancer indications to evaluate anatomy and possible postbiopsy hematoma artifacts.

**Dynamic Contrast-enhanced MR Imaging**

Angiogenesis in prostate cancer tissue is induced by secretion of vascular growth factors in reaction to the presence of local hypoxia or lack of nutrients (20). Resultant changes in vascular characteristics can be studied well with dynamic contrast-enhanced MR imaging (Fig 2). This technique exploits the dynamic uptake and rapid washout of a gadolinium chelate contrast agent to show the typical pharmacokinetics of cancerous tissue. Because the prostate as a whole is highly vascularized, a simple comparison of pre- and postgadolinium images is usually insufficient to discern prostate cancer (21,22).

A fast and direct method to characterize prostatic vascular pharmacokinetic features is high-temporal-resolution dynamic contrast-enhanced MR imaging. Dynamic contrast-enhanced MR imaging consists of a series of fast T1-weighted sequences covering the entire prostate before and after rapid injection (2–4 mL/sec) of a bolus of a low-molecular-weight gadolinium chelate such as gadoterate meglumine or gadopentetate dimeglumine (concentration, 0.1–0.2 mmol/kg) (23,24). In addition to the most frequently used fast sequences, which have a high temporal resolution (a short period of 1–4 seconds between measurements), slow sequences (temporal resolution, 30 seconds with higher spatial resolution) have also been used.

Depending on the area of anatomic coverage, the acquisition times, potential susceptibility artifacts, and desired T1 sensitivity, a choice for a faster or slower sequence must be made (25). On one hand, fast sequences may improve tissue characterization because the prostate enhances quickly with T1-weighted dynamic contrast-enhanced MR sequences. With fast sequences, accurate quantification of different pharmacokinetic enhancement parameters is possible. On the other hand, fast T1-weighted sequences have trade-offs, including reduced spatial resolution and/or anatomic coverage. Optimal spatial and temporal resolutions based on clinical indications remain subjects of future research.

Prior to postprocessing of dynamic contrast-enhanced MR imaging data, estimation of the arterial input function can be performed. In the Tofts model, the arterial input function can be calculated with a formula that uses values of plasma concentration after administration of a bolus in healthy subjects (26). In addition to the Tofts model, automatic derivation of the arterial input function from reference tissues can be performed (27). The latter method has the advantages that it needs only T1-weighted MR images and that the arterial input function is estimated accurately in a large reference tissue volume.

Assessment of signal intensity changes on T1-weighted dynamic contrast-enhanced MR images in order to estimate contrast agent uptake in vivo can be performed qualitatively, semiquantitatively or quantitatively. Qualitative analysis of signal intensity changes can be achieved by assessing the shape of the signal intensity–time curve. Quantification of signal intensity changes, which are generally represented by gadolinium concentration–time curves, requires semiquantitative
STATE OF THE ART: Multiparametric MR Imaging of Prostate Cancer

In quantitative pharmacokinetic analysis, the behavior of a volume of contrast agent in the intravascular space versus that in the extravascular extracellular space is estimated in volume units for a certain period of time. The return of the contrast agent to the extracellular extravascular space can be limited by flow, by permeability of the endothelium, or by a combination of flow and endothelial permeability. The flow-limited Kety model (28), the permeability-limited Tofts model (29) and mixed models (30,31) are applicable under these respective circumstances. Tofts et al (32) suggested the following standard pharmacokinetic quantitative parameters:

- $V_e$, which represents the volume fraction of extravascular extracellular leakage space.
- $k_{ep}$, which represents the exchange rate constant of contrast agent between the extracellular extravascular leakage space and the blood plasma (in units per minute).
- $K_{trans}$, which equals the permeability surface area product per unit volume of tissue. Under permeability-limited conditions, $K_{trans}$ equals the permeability to plasma flow per unit volume of tissue. Under permeability-limited conditions, $K_{trans}$ equals the permeability to plasma flow per unit volume of tissue. Under permeability-limited conditions, $K_{trans}$ equals the permeability to plasma flow per unit volume of tissue. Under permeability-limited conditions, $K_{trans}$ equals the permeability to plasma flow per unit volume of tissue.

Correlation of dynamic contrast-enhanced MR images with prognostic histopathologic markers of prostate cancer angiogenesis has rarely been performed. This remains an important area for future research (33).

Dynamic contrast-enhanced MR imaging is an accurate functional MR imaging technique that can be used for all clinical indications discussed in this article. In a multiparametric MR imaging examination, the high sensitivity of dynamic contrast-enhanced MR may be used for initial evaluation of potential tumor locations. Other functional MR imaging techniques may subsequently be added to increase specificity for prostate cancer localization, because sensitivity of dynamic contrast-enhanced MR imaging is low. Little standardization exists in acquisition protocols and analytic models for dynamic contrast-enhanced MR imaging.

**DW Imaging**

In DW imaging, proton diffusion properties in water are used to produce image contrast. Images that reflect proton diffusion are acquired by applying motion-encoding gradients, which cause phase shifts in moving protons, depending on the direction and quantity of their movement (36). The attenuation of the MR signal in DW imaging is expressed with the Stejskal-Tanner equation (36). The $b$ value and the apparent diffusion coefficient (ADC) are components in clinical indications such as local staging can then be improved by better prostate cancer localization characteristics obtained with dynamic contrast-enhanced MR imaging. This advantage will be addressed in the Clinical Questions section.

One of the limitations of dynamic contrast-enhanced MR imaging is related to discrimination of cancer from prostatitis in the peripheral zone and from highly vascularized BPH nodules in the transition zone (34). Other shortcomings are a limited use of standardized approaches for calibration and analysis, the shortage of uniform commercially available tools for pharmacokinetic analysis, and the lack of consensus in acquisition protocols.

**Assessment of Contrast Agent Concentration or Calculation of Different Quantitative Physiologic Parameters by Using Pharmacokinetic Compartmental Modeling**

Washout is a semiquantitative parameter that captures the curve pattern after the first peak of enhancement. Other semiquantitative parameters are (a) integral area under the gadolinium-concentration–time curves, (b) wash-in gradient (upward slope of first pass), maximum signal intensity, (c) time-to-peak enhancement, and (d) start of enhancement. Semiquantitative parameters have the advantages of being fast, relatively simple to calculate, and of being available on current MR systems. They may, however, be influenced by MR unit settings (22).

In multiparametric MR imaging, assessment of contrast agent concentration or calculation of different quantitative physiologic parameters by using pharmacokinetic compartmental modeling can be improved by better prostate cancer localization characteristics obtained with dynamic contrast-enhanced MR imaging. This advantage will be addressed in the Clinical Questions section.
this equation. While the $b$ value expresses the amount of diffusion weighting, ADC reflects the movement of the water molecules within the interpulse time. Because ADC quantifies the flow as well as the distance a water molecule has moved, it represents both capillary perfusion and diffusion characteristics (37). Fitting the Stejskal-Tanner equation for every pixel on two or more DW images acquired with different $b$ values results in an ADC map. For prostate cancer, DW imaging $b$ values between 500 and 800 sec/mm² are typically used (38). $b$ Values of 1000 and even 2000 sec/mm² may increase the accuracy of prostate cancer detection (39). Especially within the transition zone, high $b$ values may help improve differentiation of BPH from prostate cancer (40).

Healthy prostate tissue in the peripheral zone, which is rich in tubular structures, allows extensive diffusion of water molecules within the gland tubules. Consequently, ADCs in healthy peripheral zone tissues can be high. Prostate cancer tissue destroys the normal glandular structure of the prostate and replaces ducts. It also has a higher cellular density than does healthy prostate peripheral zone tissue (38). On ADC maps, therefore, prostate cancer often shows lower ADCs in comparison to surrounding healthy peripheral zone prostate tissue (41). Examples of this are presented in Figure 3. Recently, 3 T DW imaging ADCs were shown to correlate significantly with the cellular density of prostate cancer in radical prostatectomy specimens (42).

Because the acquired ADC depends on the specific pulse sequence parameters (especially the $b$ values), the specific MR systems used, and the magnetic field strength, the ADCs of healthy and cancerous tissue have varied among reported studies. Furthermore, there is an overlap in the ADCs of healthy tissue and those of prostate cancer, within and between subjects, which limits the determination of a single threshold ADC for malignancy (43).

Mean ADCs for prostate cancer versus those for healthy prostate tissue obtained at different field strengths, with or without the use of an endorectal coil in different anatomic regions are shown in Table 1. Owing to variations in ADCs of benign prostate tissue in the peripheral and transition zones, the area under the receiver operating characteristic curve (AUC) for differentiation of prostate cancer from benign tissue can vary by anatomic location within the prostate gland and are found to be lower in the prostatic base (AUC of 0.725 in prostate base vs 0.952 and 0.906 for overall peripheral and transition zones, respectively) (44). The reported differences in detection accuracies with DW imaging might be explained by the different tissue composition in different anatomic zones of the prostate. It has been hypothesized that a higher degree of proton motion in the extracellular water compartment occurs as opposed to that in intracellular water, where movement is restricted by cell membranes or other intracellular structures (38). As a result of variation in glandular tissue within a healthy peripheral zone to muscular or fibrous tissue within the transition zone, the ratio of intracellular versus extracellular water also differs. This variation might also explain the variability of ADCs in healthy prostate tissue that have been reported. Relative ADC thresholds calibrated to an individual gray-scale value may be a way to overcome intra- and interindividual variation and overlap of ADCs of cancer and healthy prostate tissue (45).

DW imaging is a fast, simple, and readily available MR imaging technique for prostate cancer. Nevertheless, DW imaging of the prostate has the limitation of low in-plane spatial resolution, even at 3 T. Consequently, DW imaging is not a preferred technique for
is very small, echo-planar imaging is very sensitive to magnetic field inhomogeneities. As a result, artifacts occur in areas with large variations in magnetic susceptibility, such as in tissue-air interfaces (air in the rectum or endorectal coil) or in chemical shift in areas with water-fat interfaces. Parallel imaging and short-imaging-time protocols are used to overcome these off-resonance artifacts (46).

Correlation of DW imaging results and histopathologic findings as well as to prognostic histologic prostate cancer markers such hypoxia-inducible factors, should be another area for future research.

Of all functional MR imaging techniques DW imaging is the most practical and simple in its use. Within a multiparametric MR imaging examination DW imaging may be used for all clinical indications discussed in this article. DW imaging has the disadvantages of being susceptible to motion and to magnetic field inhomogeneities.

Proton MR Spectroscopic Imaging

In MR spectroscopic imaging, spectral profiles are measured in two or three spatial dimensions. These spectral profiles reflect resonance frequencies that are unique for protons in different metabolites present at the sampled location. The specific resonance frequencies or chemical shifts are given relative to a reference frequency in parts per million (ppm). In human prostate examinations, MR spectroscopic imaging is usually performed in a volume that covers the whole prostate, which is subdivided up into a three-dimensional grid of multiple voxels. With the introduction of the endorectal coil for prostate MR examinations, it became possible to obtain in vivo MR spectroscopic imaging spectra of small voxels in the prostate (less than 1 cm$^3$) with sufficient signal to noise (47–49). The dominant peaks observed in these spectra are from protons in citrate (approximately 2.60 ppm), creatine (3.04 ppm) and choline compounds (approximately 3.20 ppm). Polyamine signals (mostly from spermine) also may be observed (approximately 3.15 ppm) at various relative intensities, depending on the acquisition conditions. Compared with healthy peripheral tissue or BPH tissue, citrate signals are reduced and those of choline compounds are often increased in prostate cancer tissue (Fig 4) (50). Citrate is produced in epithelial cells as an intermediate product in the Krebs cycle due to aconitase inhibition. It then accumulates in the luminal space of the prostate. The lower citrate peak in cancer tissue may thus be caused by altered metabolism, as well as by a reduction of luminal space, which commonly occur in prostate cancer. Choline compounds are involved in the biosynthesis and degradation of phospholipids, which are required for the build-up and maintenance of cell membranes. An increased cell-turnover in prostate cancer results in an increased concentration of free choline-containing molecules within the cytosol and the prostate interstitial tissue.

Because differentiation of choline peaks from creatine peaks on spectra obtained at common clinical field strengths is often hampered by their bandwidths and by weaker signals from polyamines between them, the choline plus creatine–to-citrate ratio is mostly used as a metabolic biomarker for prostate cancer. An example of this is presented in Figure 4. In the analysis of patient data, it should be taken into account that different anatomic zones of the healthy prostate have different amplitudes for citrate, creatine, and choline, which are reflected in different choline plus creatine–to-citrate ratios. High citrate concentrations are found in the glandular tissues of the prostate such as the peripheral zone, which contains epithelial cells and secretory ducts. Therefore, citrate concentrations are highest in the peripheral zone and lower in the central zone. In the transition zone, the citrate concentration may be higher in case of glandular proliferation and lower in the case of stromal proliferation (51). Furthermore, because of the sensitivity profile of the surface coil, the spectral signal intensity will drop the farther away the tissue is from the ERC. Since the prostate is relatively small and embedded in adipose tissue,
much effort has been put into suppressing spectral contamination, not only of the high water signal, but also of strong lipid signals. Therefore, radiofrequency pulse schemes that selectively invert and dephase water and lipid signals have been developed (52,53). Frequency-selective suppression methods, such as Mescher-Garwood (or MEGA) pulses (52) or later band selective inversion with gradient dephasing (or BASING) are generally applicable because no high-performance gradients are necessary. Spectral-spatial pulses have the advantage of increased bandwidth, which results in decreased chemical shift–dependent localization errors. Three-dimensional MR spectroscopic imaging sequences are currently preferred over two-dimensional sequences because of the possibility of complete coverage of the entire prostate gland (47,54). Three-dimensional acquisitions can be performed in approximately 10–15 minutes with a resolution as low as 0.4 cm³ with sufficient signal-to-noise ratio at 1.5 T (54).

MR spectroscopic imaging has several limitations. Spectral quality depends on magnetic field homogeneity, which must be optimized for each patient by shimming. Considerable local magnetic field distortions may occur due to hemorrhage, which is why the examination should be performed with sufficient delay from the time of biopsy. The clinical performance of MR spectroscopic imaging of the prostate can be improved by optimizing field shimming or by means of correction procedures, in addition to better signal-to-noise ratio and chemical shift dispersion, by using stronger magnetic fields (55). Currently, the interpretation of MR spectroscopic imaging results requires special expertise and is time consuming. Automated measurement procedures, rapid display of examination results, and proper training of clinical users are important to transform MR spectroscopic imaging into a practical and widespread clinical tool. To this day, these requirements are generally not met.

MR spectroscopic imaging is an accurate technique that may be used for all clinical indications mentioned in this article. MR spectroscopic imaging needs, however, relatively more time and expertise than do other functional MR imaging techniques, which limits its clinical applicability.

Combined Multiparametric MR Imaging

Because the functional MR imaging techniques we have discussed all have their strengths and shortcomings, they are combined in a multiparametric MR imaging prostate examination to increase accuracy. A multiparametric MR imaging prostate examination consists of T1- and T2-weighted imaging combined with one or more functional MR imaging techniques.

Within the variety of possible MR imaging protocols and combinations of different techniques, consensus guidelines are needed to increase accuracy and unity in the field (56). Because formal practice guidelines for multiparametric prostate imaging are currently unavailable, the following suggestions for possible prostate multiparametric MR imaging protocols for different clinical indications can be recommended. Patients with a clinical indication of prostate cancer detection, who often have previously undergone one or more systematic random biopsies with negative results, may have a high a priori risk for transition zone cancer (57). In these patients, it is essential not only to use techniques such as T2-weighted and dynamic contrast-enhanced MR imaging, which may yield false-positive or false-negative results within the transition zone, but also DW imaging (with a high b value), which may be a valuable technique in difficult detection cases.

In patients referred for pretreatment staging, it is important to use an endorectal coil in combination with anatomic T2-weighted MR imaging. Because accurate localization may improve accurate staging it may be important to add at least one multiparametric MR imaging technique (Fig 5). Patients with a clinical indication for active surveillance or focal therapy need evaluation of the stage of the cancer and its aggressiveness. Preferably, an endorectal coil could be used in combination with more than one multiparametric technique that yields findings related to prostate cancer Gleason score (DW imaging and/or MR spectroscopic imaging) (Fig 6).

The optimal strength of multiparametric MR imaging is achieved by combining the information obtained with the various techniques. Computer programs, which allow evaluation of two or more multiparametric images in one view, need to be developed for the integrated interpretation of anatomic and functional findings. An example of how this could be accomplished is presented in Figure 7. Development of supportive techniques like computer aided diagnosis (58–60) is needed to achieve fast and reproducible diagnostics from large quantities of complex data. Furthermore, the education, experience, and
dedication of radiologists are essential for correct interpretation of findings from multiparametric MR imaging of the prostate (61).

Minimal requirements for a multiparametric MR imaging protocol include a combination of T1- and T2-weighted MR imaging with DW and dynamic contrast-enhanced MR imaging. For detection and localization indications, the use of a phased-array coil is sufficient; for staging indications, combination with an endorectal coil may be preferred.

**MR Imaging–guided Biopsy**

As mentioned earlier, systematic random biopsy is prone to sampling error, which often results in inaccurate prostate cancer detection and Gleason score grading (10). MR-guided prostate biopsy can potentially improve prostate cancer detection, because multiparametric MR imaging–guided biopsy can be targeted toward previously determined regions that are suspicious for cancer. MR-guided biopsy is technically feasible and can be performed on a routine basis (Fig. 8). Owing to its limited availability and long examination time, this technique is typically used in patients with one or more previous negative systematic random biopsy sessions. Transrectal MR-guided biopsy performed at 1.5 T has shown promising cancer detection rates of 38%–59% (57,62–64). These detection rates are promising in comparison to those of systematic random biopsy rates of 22%–29% (9,65) after one session and 10%–17% after two sessions (9,65).

Use of multiparametric MR imaging in MR-guided biopsy planning has been studied by Franiel et al (66) in a prospective study of 1.5-T MR imaging in 54 patients with a median of two previous negative random systematic transrectal US-guided biopsies. Their ground truth was based on MR-guided biopsy of suspicious identifiable lesions from at least one multiparametric MR imaging technique only. They concluded that a combination of T2-weighted and dynamic contrast-enhanced MR imaging or MR spectroscopic imaging reduced the number of areas that need to be subject to biopsy by 13%–15% while only missing 6% of cancers, in comparison to multiparametric MR imaging with all three techniques.

A limitation of MR-guided biopsy is that a multiparametric MR imaging and the MR-guided biopsy need to be performed in separate sessions because image postprocessing and exact tumor localization demand time. Another disadvantage is movement of the prostate during the biopsy procedure (67).

MR imaging findings have also been used to help direct biopsies under transrectal US guidance with reasonable to good detection rates of 25%–55% (68,69). Moreover, Gleason score concordance with radical prostatectomy findings may be improved with MR imaging guidance of transrectal US-guided prostate biopsy (70). Experimental fusion of MR and transrectal US data (71), in which distances between corresponding data points for each technique are rendered as small as possible by means of registration, is used to obtain more accurate MR-guided transrectal US prostate biopsy results (72).

Transrectal MR-guided biopsy improves prostate cancer detection; however, its availability is limited, and examination times are long. MR guidance of prostate biopsy is a very promising method to improve determination of the true pretreatment Gleason score.

**Clinical Questions**

**Detection**

As stated earlier, clinical prostate cancer detection is currently performed by using tools with limited accuracy. Because the specificity of PSA measurement is
low, it is often the case that many unnecessary repeat systematic random biopsies are required to establish a diagnosis (9).

Individual multiparametric MR imaging techniques such dynamic contrast-enhanced, DW and MR spectroscopic imaging have been shown (73–75) to be of possible additional value in prostate cancer detection (Fig 9). Because these MR techniques have a relatively high specificity in comparison with PSA measurement, they could prevent the unnecessary performance of systematic random biopsies and delay in diagnosis and treatment. Furthermore, results of prospective separate functional MR imaging studies for prostate cancer detection are difficult to compare, since criteria for cancer detection, methods of analysis, sample sizes, and mean PSA levels of patient groups differ or are not always presented.

It is essential to know if combinations of more than one functional MR technique could improve results even further. In a logistic regression analysis, ADC value was the best performing (area under the receiver operating characteristic curve $[A_z] = 0.69$) single parameter for prostate cancer detection when compared with T2-weighted imaging findings, $K_{\text{trans}}$, and extracellular extravascular space volume fraction $v_e$ (73). In this study (73), a model based on T2-weighted MR imaging findings, ADCs, and $K_{\text{trans}}$ performed best ($A_z = 0.706$). Although this study had a moderate sample size ($n = 42$) and was retrospective in character, it is one of the few prostate cancer detection studies in which prostatectomy specimens were used as the reference standard. In a recent evaluation of multiparametric MR imaging at 3 T (76), the addition of dynamic contrast-enhanced and/or DW imaging to T2-weighted MR imaging significantly improved prostate cancer detection sensitivity from 63% to 79%–81% in the peripheral zone, while maintaining a stable specificity. In the transition zone, however, multiparametric MR imaging did not improve prostate cancer detection. This study was performed in 57 patients, with prostatectomy specimens as ground truth. The combination of MR spectroscopic imaging with T2-weighted endorectal MR imaging has shown higher sensitivity (72%–89%) and equal specificity (79%–93%) for prostate cancer detection than was shown for anatomic MR imaging alone (sensitivity, 57%–84%; specificity, 50%–94%) (77,78).

Multiparametric MR imaging techniques may also contribute in detection of transition zone prostate cancers. The combined use of DW, dynamic contrast-enhanced, and T2-weighted MR imaging led to increased accuracy in detection of transition zone cancer, from 64% to 79%, in a small ($n = 23$) retrospective study (79).

Multiparametric MR imaging may potentially increase prostate cancer detection accuracy compared with the accuracy of T2-weighted MR imaging only. However, future research is needed to confirm initial results.

**Localization and Local Staging**

Prostate cancer localization is the most important clinical indication for multiparametric MR imaging of the prostate. First, accurate definition of prostate cancer location helps improve cancer
detection in targeting prostate biopsies with MR imaging guidance. Second, accurate definition of a prostate cancer location also helps improve cancer staging, because better assessment of prostate cancer location(s) near the neurovascular bundle is possible in patients in whom nerve-sparing surgery is planned. Third, improved evaluation of prostate cancer location helps improve and support focused intensity-modulated radiation therapy planning of the dominant prostatic lesion and improves guidance of minimally invasive focal therapies.

In a large retrospective study in 106 patients in which prostatectomy findings were the reference standard, MR imaging localization of prostate cancer was significantly more accurate than digital rectal examination and systematic random biopsy results in the whole prostate except for the apex. Sensitivity and especially specificity of endorectal T2-weighted MR imaging prostate cancer localization vary, ranging from 34% to 91% and 27% to 91%, respectively (81–84). Variations of results in these prospective studies, in which prostatectomy findings served as reference standard, might be partially explained by the fact that image analysis was based on different numbers of regions of interest, different cutoff points for a positive result, and inclusion or exclusion of prostate cancer localization in the transition zone. Moreover, results vary as correlation of MR imaging findings with prostatectomy findings is difficult owing to different angles and section intervals of MR sections and prostatectomy slices and to deformation and shrinkage during histopathologic processing of the prostate specimens. Correction for this variability has been attempted by using a shrinkage factor (83,85). In a recent prospective study (84), correlation of MR imaging and prostatectomy findings was performed in an innovative and possibly more accurate way. Aside from dividing the prostate into 30 regions, including peripheral and transition zones, the authors also used an alternative-neighbor analytic approach to correct for prostate shrinkage and deformation. In this approach, tumors visible on MR image and seen in neighboring regions of the positive prostatectomy specimen were also considered to be positive MR results.

Localization merits of multiparametric MR imaging techniques may be used to draw the attention of the radiologist to a suspicious region. This is illustrated in Figures 5, 9, and 10.

Localization accuracy with dynamic contrast-enhanced MR imaging increased to 72%–91%, as compared with 69%–72% for anatomic T2-weighted MR imaging only (85–88). The addition of DW imaging (83) to T2-weighted MR imaging significantly improved sensitivity to 81% (sensitivity for T2-weighted MR imaging alone, 54%), whereas specificity was slightly lower for T2-weighted MR imaging combined with DWI (84%) than for T2-weighted MR imaging alone (91%) in this prospective prostatectomy-referenced study (83). Also, in other prospective studies (89,90), the addition of DW imaging to T2-weighted MR imaging improved prostate cancer localization performance, with $A_v$ values of 0.66–0.79. However, in a recent retrospective 3-T study in 51 patients, with prostatectomy specimens as reference standard (91), DW imaging did not add value to T2-weighted MR imaging for prostate cancer localization. $A_v$ values were 0.76–0.79 for T2-weighted...
MR imaging and 0.78–0.79 for T2-weighted MR imaging combined with DW imaging ADC maps. The high percentage of Gleason score 6 (3+3) cancers (36%, of which only 53%–63% were detected) may explain the poor incremental value of DW imaging ADC maps in this study.

MR spectroscopic imaging has shown higher specificity (68%–99%) and lower sensitivity (25%–80%) for prostate cancer localization, when compared with anatomic T2-weighted MR imaging (specificity, 61%–90%; sensitivity, 68%–87%) in prospective studies with prostatectomy specimens as reference standard (82,84,85,92). However, a multicenter trial that included 110 patients, with prostatectomy findings as reference standard (93), did not show any benefit for the addition of 1.5-T MR spectroscopic imaging to T2-weighted MR imaging in prostate cancer localization (A$_r$ = 0.60 for T2-weighted MR imaging alone vs 0.58 for combined T2-weighted and MR spectroscopic imaging, P = .09). The omission of a multicenter validation and use of a threshold for increased metabolic ratios as a criterion for malignancy as well as of a clear definition of tumor focus size may have negatively influenced the quality of MR spectroscopic imaging in this trial. In a recent multiparametric 3-T MR imaging study with 57 patients (76), DW and dynamic contrast-enhanced MR imaging increased the accuracy of prostate cancer localization in the peripheral zone but failed to do the same in the transition zone. By using prostatectomy specimens as standard of reference and scoring four quadrants for both peripheral and transition zones, A$_r$ values for the peripheral zone increased from 0.81 to 0.91–0.92 by adding DW and/or dynamic contrast-enhanced MR imaging to T2-weighted MR imaging. In the transition zone, however, localization accuracy decreased from A$_r$ of 0.84 for T2-weighted MR imaging alone to 0.70–0.75 when dynamic contrast-enhanced imaging was added. With the addition of DW imaging to T2-weighted imaging, A$_r$ values for cancer localization in the transition zone increased slightly from 0.84 to 0.88. By improving localization multiparametric MR imaging techniques may also contribute to improved local staging accuracy.

For appropriate therapy planning it is important to know if prostate cancer is confined to the gland (stages T1
and T2) or if there is extraprostatic extension (stages T3 and T4) (94). Current clinical staging, generally based on digital rectal examination, PSA and transrectal US findings, results in frequent understaging (59%) and some overstaging (5%) (95).

The main application of T2-weighted MR imaging is in local staging of prostate cancer. The most widely used criteria for extracapsular spread are (asymmetric) low signal intensity in the seminal vesicles, asymmetry of the neurovascular bundle, obliteration of the rectoprostatic angle (Fig 11), irregular bulging of the prostatic contour (Fig 11), low signal intensity indicative of cancer in the rectoprostatic fat, and overt extracapsular cancer. The last three criteria have the highest sensitivity (96) while all criteria have high specificity.

There has been a longstanding debate on whether or not to use an endorectal coil for prostate cancer staging since its use results in a more labor-intensive and costly examination. In a meta-analysis, Engelbrecht et al (97) reported on 146 studies performed at 1.5 T and found that the use of turbo spin-echo sequences, an endorectal coil and multiplanar acquisitions all significantly increased staging performance. The application of an integrated endorectal-pelvic phased-array coil significantly improved staging performance, particularly sensitivity, compared with that of a pelvic phased-array coil alone: $A_1$ increased from 0.57 to 0.74 at 1.5 T and from 0.62 to 0.68 at 3 T ($P < .001$) (98). Although, in the largest prospective prostate cancer staging study performed at 1.5 T of which we are aware (99), where MR imaging with a body coil only and with an endorectal coil only were compared, body coil imaging performed better (accuracy, 62%) than did endorectal coil imaging (accuracy, 52%). In the past decade since this trial, technologic developments such as the use as higher field strengths, improved pelvic phased-array coils and multiparametric MR imaging techniques have improved staging accuracy considerably. However, accuracy results vary between different studies. Table 2 provides an overview of recent prostate cancer staging MR imaging studies at both field strengths (100–107). The results of the MR prostate cancer staging studies, as presented in Table 2, seem conflicting. One should be careful, as difficulty remains in comparing and interpreting results of these studies because different field strengths, comparisons of coil types, and endpoints were used for prostate cancer staging.

To our knowledge, only two studies have directly compared 3-T and 1.5-T MR staging of prostate cancer (108,109). This comparison was suboptimal, because use of a pelvic phased-array coil at 3 T was compared with use of a pelvic phased-array coil and/or an endorectal coil at 1.5 T. Conclusions on the effects of higher field strength on MR staging of prostate cancer remain difficult to infer because research on this topic is still immature.

Multiparametric MR imaging may also improve prostate cancer staging. In a large prospective study with 99 patients (110), dynamic contrast-enhanced MR imaging combined with T2-weighted MR imaging significantly improved the accuracy of prostate cancer staging compared with that of T2-weighted MR imaging alone. $A_1$ values for less
experienced readers were 0.82 for dynamic contrast-enhanced plus T2-weighted MR imaging and 0.66 for T2-weighted imaging alone respectively (P ≤ 0.01). In a prospective study with 53 patients (111), addition of three-dimensional MR spectroscopic imaging results to T2-weighted MR imaging results significantly improved accuracy for predicting extracapsular extension for both experienced and less-experienced readers (A 2 increase from 0.78 to 0.86 and 0.62 to 0.75, respectively, for T2-weighted imaging only vs combined imaging).

Drawbacks of T2-weighted MR imaging for prostate cancer localization and local staging include differentiation of inflammatory changes from cancer. Furthermore, high inter- and intraobserver variability may lead to under- or over-estimation of cancer stage (112). Also, postbiopsy hemorrhage can decrease staging accuracy. Finally, T2-weighted MR imaging cannot be used to detect microscopic capsular invasion. As mentioned earlier, pitfalls of multiparametric MR techniques also affect the ability to facilitate prostate cancer localization and local staging. (see Figs 5, 10).

Of all clinical indications for multiparametric MR imaging, localization is the most important. Accurate prostate cancer localization results in more accurate prostate cancer staging and in more accurate MR guidance of prostate biopsy and therapy.

**Determination of Prostate Cancer Aggressiveness**

Prostate cancer is graded according to the Gleason score, a combination of the two most prevalent Gleason grades (at prostatectomy) or the most prevalent and the highest grade (at prostate biopsy), based on architectural characteristics of prostate cancer tissue (113,114). Sampling error in biopsy specimens obtained at systematic random biopsy occurs in approximately in 64% of procedures (10) and results in a changed Gleason score at histopathologic evaluation of the prostatectomy specimen. This results in incorrect evaluation of prostate cancer aggressiveness, which may cause under- or overtreatment (115).

On T2-weighted MR images, signal intensity changes and detection rates for prostate cancer have been associated with its aggressiveness. In a retrospective study with 74 patients, in which prostatectomy specimens were used as standard of reference (14), low-grade cancers were detected at a rate of 43%, while high-grade cancers were detected at a rate of 79%. In another retrospective study, which also used prostatectomy specimens as reference standard (116), higher Gleason scores were associated with lower tumor-to-muscle signal intensity ratios on T2-weighted MR images. In a large retrospective study with 220 patients (117), T2-weighted MR imaging and MR spectroscopic imaging scores based on a three-point scale for clinical prostate cancer aggressiveness were significantly correlated to biologic markers such as androgen receptor levels, which were associated with prostate cancer progression. In that study, the combination of biologic markers with T2-weighted MR imaging and MR spectroscopic imaging results yielded an A 2 of 0.91 for discrimination of clinically unimportant prostate cancer, which was defined as...
cancer confined to the organ and 0.5 cm³ or less in volume without poorly differentiated parts at pathologic examination. Moreover, at MR spectroscopic imaging, the choline-plus-creatine-to-citrate ratios have been shown to be associated with Gleason score (118,119). In a retrospective study of 43 patients with biopsy-proved prostate cancer, Kohus et al (120) showed that 3-T MR spectroscopic imaging is an accurate technique for discriminating patients with Gleason grade 2 or 3 cancer from patients with Gleason score 4 or 5 cancer, as determined with prostatectomy specimens. By using a standardized-threshold approach involving both the choline-plus-creatine-to-citrate ratio and the choline-to-citrate ratio, an \( A_c \) of 0.78 was achieved for discrimination of Gleason score 2–3 from Gleason score 4–5 prostate cancers.

Results for ADC as a possible marker of cancer aggressiveness are very promising: In a retrospective study of 3-T DW imaging \( (b = 0, 50, 500, \text{ and } 800 \text{ sec/mm}^2) \) Hambrock et al (45) correlated median ADCs with prostatectomy Gleason grades in peripheral zone prostate cancers on a slice-by-slice basis in 51 patients. Cancers with Gleason score 2–3 components were discerned from cancers with Gleason score 4–5 components, with an \( A_c \) of 0.90. Furthermore, in a study of 1.5-T DW imaging \( (b = 0 \text{ and } 600 \text{ sec/mm}^2) \) in 110 patients with 197 tumors, Verma and Rajesh (121) found a negative correlation \( (r = −0.39) \) between mean ADC and Gleason score for peripheral zone cancers on prostatectomy specimens. A similar association could not be found for cancers in the transition zone. An \( A_c \) of 0.78 was achieved by using both cancer volume and ADC as predictors of tumor aggressiveness (Gleason score > 6). While preliminary studies in the field of prostate cancer aggressiveness show promising results (45), different parameters from different multiparametric techniques show some overlap among Gleason scores. Because a certain value of an MR parameter, such as ADC, cannot be precisely associated with one Gleason score component, multiparametric MR imaging cannot yet be applied to the determination of prostate cancer aggressiveness in a general

---

**Figure 10:** Multiparametric MR imaging for prostate cancer localization in a 71-year-old man with stage T1, Gleason score of 7 (3+4) disease in left prostate base who underwent endorectal MR staging: pitfalls in dynamic contrast-enhanced MR imaging localization of prostate cancer. Dynamic contrast-enhanced MR imaging results in enhancement in multiple areas and is therefore indeterminate when performed in addition to T2-weighted MR imaging. DW imaging correctly localizes this cancer and shows its aggressiveness. (a) Axial T2-weighted turbo spin-echo MR image \( (4260/99; \text{ flip angle, } 120°) \) at midprostate shows low-signal-intensity lesion in left peripheral zone (outline) next to region of high signal intensity in peripheral zone, with minimal signs of extracapsular extension (arrow). (b) Axial MR image with a superimposed \( K^{\text{trans}} \) map \( (38/1.35; \text{ flip angle, } 14°) \) at same level as a shows multiple enhancing areas in both peripheral and transition zones. Tumor area \( (T) \) also shows enhancement. Tumor localization is indeterminate. (c) Axial ADC map \( (2400/81; b = 0, 50, 500, \text{ and } 800 \text{ sec/mm}^2) \) at same level as a shows restricted diffusion in left lateral peripheral zone \( (T) \) (mean ADC = 0.39 × 10⁻⁶ mm²/sec), which indicates intermediate tumor aggressiveness. (d) Axial whole-mount histopathologic slice at level corresponding to that of a–c shows a Gleason score 7 (3+4), stage T3A prostate cancer in the left laterodorsal peripheral zone (outline), which confirms the T2-weighted and DW imaging data.

**Figure 11:** Multiparametric MR imaging in prostate cancer staging in a 70-year-old man with PSA level of 12 ng/mL and well-differentiated prostate carcinoma. (C) Axial T2-weighted turbo spin-echo MR image \( (4260/99; \text{ flip angle, } 120°) \) shows low-signal-intensity region (outline) in left peripheral zone. Bulging and obliteration of rectoprostatic angle (open arrows) indicate extracapsular extension. There is invasion of the neurovascular bundle (solid arrow). At MR imaging, stage T3A prostate cancer was reported. Radical prostatectomy revealed a solitary adenocarcinoma with Gleason score 7 (3+4) with extraprostatic extension (stage T3a).
clinical environment. However, this technique is very helpful for assessing tumor grade and guiding biopsy to the most aggressive part of the tumor.

**Active Surveillance**

With the observation that low-risk cancers do not progress rapidly when treatment is deferred (122,123), implementation of active surveillance protocols has become more widespread. The aim of this approach is to minimize overtreatment by means of active observation of low-risk cancers and to intervene with curative therapy when a presumably low-risk cancer shows signs of progression. Low-risk cancer is frequently defined as a cancer with a clinical stage of T2 or lower, a Gleason score of 6 or less without a Gleason 4 or 5 component, a PSA level of 10 ng/mL or less, a PSA density ≤0.15 ng/mL/mL or less, and systematic random biopsy criteria of two or fewer cores with prostate cancer and 50% volume of cancer or less per core (124).

The cornerstone of active surveillance protocols is the accurate identification of low-risk cancers. A frequent cause for inaccurate estimation of prostate cancer aggressiveness is sampling error at systematic random biopsy with subsequent undergrading of Gleason score. In addition, cancer volume is also underestimated owing to sampling error in systematic random biopsies, because cancer volume is estimated by measuring the number and volume percentages of cancer tissue of cancer-positive biopsy cores (10). In patients in whom risk stratification was incorrectly determined, repeat biopsies may eventually show evidence of high-risk disease, which then triggers a delayed intervention with, perhaps, a missed opportunity for definitive curative therapy (125–127).

Multiparametric MR imaging can potentially aid in adequate risk stratification for patient selection in active surveillance by improving prostate cancer staging and by characterizing cancer aggressiveness (Fig 6). An example of improved staging by using MR imaging

<table>
<thead>
<tr>
<th>Study and Year</th>
<th>Field Strength (T)</th>
<th>No. of Subjects</th>
<th>PA Coil</th>
<th>ER Coil</th>
<th>MR Technique</th>
<th>Sensitivity (%)*</th>
<th>Specificity (%)*</th>
<th>Accuracy (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al (107), 2010</td>
<td>1.5</td>
<td>91</td>
<td>Yes</td>
<td>Yes</td>
<td>T2 weighted, DW</td>
<td>PA: ECE in 30</td>
<td>PA: ECE in 90</td>
<td>NR</td>
</tr>
<tr>
<td>Augustin et al (100), 2009</td>
<td>3.0</td>
<td>27</td>
<td>Yes</td>
<td>No</td>
<td>T2 weighted</td>
<td>ECE in 67</td>
<td>ECE in 100</td>
<td>ECE in 85</td>
</tr>
<tr>
<td>Torricelli et al (104), 2008</td>
<td>3.0</td>
<td>42</td>
<td>Yes</td>
<td>No</td>
<td>T2 and T1 weighted</td>
<td>ECE in 69</td>
<td>ECE in 92</td>
<td>ECE in 83</td>
</tr>
<tr>
<td>Park et al (109), 2007</td>
<td>3.0</td>
<td>54</td>
<td>Yes</td>
<td>No</td>
<td>T2 weighted</td>
<td>ECE in 81</td>
<td>ECE in 67</td>
<td>ECE in 72</td>
</tr>
<tr>
<td>Park et al (109), 2007</td>
<td>3.0</td>
<td>54</td>
<td>Yes</td>
<td>No</td>
<td>T2 weighted</td>
<td>ECE in 71</td>
<td>ECE in 73</td>
<td>ECE in 72</td>
</tr>
<tr>
<td>Heijmink et al (102), 2007</td>
<td>3.0</td>
<td>46</td>
<td>Yes</td>
<td>Yes</td>
<td>T2 weighted</td>
<td>PA: 13 (2/15)</td>
<td>PA: 100</td>
<td>ECE in 91</td>
</tr>
<tr>
<td>Futterer et al (98), 2007</td>
<td>1.5</td>
<td>81</td>
<td>Yes</td>
<td>Yes</td>
<td>T2 weighted</td>
<td>ERC: 80 (12/15)</td>
<td>ERC: 100</td>
<td>ECE in 83</td>
</tr>
<tr>
<td>Bloch et al (106), 2007</td>
<td>1.5</td>
<td>32</td>
<td>Yes</td>
<td>Yes</td>
<td>T2 weighted, dynamic contrast enhanced</td>
<td>ECE in 91 (11/12)</td>
<td>98 (44/45)</td>
<td>83 (67/82)</td>
</tr>
<tr>
<td>Chandra et al (101), 2007</td>
<td>1.5</td>
<td>38</td>
<td>Yes</td>
<td>Yes</td>
<td>T2 weighted, MR spectroscopic imaging</td>
<td>ECE in 69; SVI in 60</td>
<td>ECE in 82 SVI in 100</td>
<td>ECE in 76 SVI in 95</td>
</tr>
<tr>
<td>Latcham-setty et al (105), 2007</td>
<td>1.5</td>
<td>80</td>
<td>NR</td>
<td>Yes</td>
<td>T2 weighted</td>
<td>ECE in 71</td>
<td>ECE in 78</td>
<td>ECE in 73</td>
</tr>
<tr>
<td>Futterer et al (96), 2006</td>
<td>3.0</td>
<td>32</td>
<td>Yes</td>
<td>Yes</td>
<td>T2 and T1 weighted</td>
<td>ECE in 88 (7/8)</td>
<td>96 (23/24)</td>
<td>94 (30/32)</td>
</tr>
</tbody>
</table>

*Data in parentheses are numbers from which percentages were calculated.

†Obtained by experienced radiologist.

‡Maximal values for an examination performed independently by four radiologists.

§Maximal percentages for assessment of extracapsular extension adjusted to prevalence of disease in the study population at large.

||
in active surveillance is in a prospective study by Berglund et al (128). In that study, 18 (39%) of 66 patients in whom MR imaging findings were suspicious for extracapsular extension were upgraded or upstaged because of progression at histologic examination of the repeat biopsy specimen.

During follow-up in active surveillance, detection of cancer progression within the curative window is essential. MR imaging can also be valuable in this application. Recently, Giles et al (129) showed that ADCs at repeat biopsy were significantly lower in patients with a Gleason score increase than in those with a stable score \( P < .001 \). In that study, both tumor volume \( (P = .002) \) and ADCs calculated from DW imaging \( (300–800 \text{ sec/mm}^2) \) \( (P = .02) \) were significant independent predictors of progression of active surveillance patients. Progression was defined biochemically (PSA increase, >1 ng/mL per year) and/or histopathologically (repeat biopsy Gleason grade > 4 or cancer presence in more than 50% of biopsy cores). In another active surveillance study in 86 patients with a mean follow-up of 29 months \( (130) \), DW imaging tumor ADC data were significant predictors of a Gleason score 4 component at repeat biopsy \( (A = 0.70, P < .001) \) and of the need for initiation of radical treatment during follow-up \( (A = 0.83, P < .001) \). Patients were included in this study if they met the following criteria: PSA level of 15 ng/mL or lower, Gleason score of 7 or lower with a primary Gleason score of 3 or less, 50% or fewer of biopsy cores positive at systematic random biopsy, three monthly PSA measurements, repeat systematic random biopsies 12–24 months after inclusion, and performance of DWI imaging before inclusion. Similar results were found in another retrospective study \( (131) \), in which an increase to Gleason score 7 or higher at subsequent repeat systematic random biopsy in 114 active surveillance patients was associated with T2-weighted MR imaging results although not with transrectal US or MR spectroscopic imaging results.

These studies may underestimate results because systematic random biopsy specimens, instead of a prostatectomy specimen, were used as the reference standard. On the other hand, in a large retrospective study, Cabrera et al (132) found that T2-weighted MR imaging and MR spectroscopic imaging performed at baseline were of no additional prognostic value to active surveillance because the presence of cancer on MR images could not be associated with biochemical outcome in multivariate analysis. Biochemical outcome was defined according to serial PSA measurements, which were classified as stable or progressive by using slopes of regression lines. These results conflict with those of previous retrospective studies \( (130,131) \). The field strength of 1.5 T used by Cabrera et al and the use of PSA kinetics instead of histologic findings as a measure of prostate cancer progression might partly explain these conflicting results. Despite general promising results, incorporation of multiparametric MR imaging into active surveillance protocols for low-risk prostate cancer is still in an early phase.

Multiparametric MR imaging and MR-guided biopsy may improve initial diagnosis and accurate monitoring of prostate cancer stage and aggressiveness in active surveillance. Future research addressing the use of multiparametric MR imaging in selection and follow-up of patients with low-risk prostate cancer as part of active surveillance protocols is needed.

### Conclusion

In this review, we have presented and discussed available data on the additional value of the different functional MR imaging techniques in various clinical diagnostic prostate cancer problems.

To increase MR imaging accuracy for the different clinical prostate cancer indications, one or more functional MR imaging techniques should be combined with T2-weighted MR imaging in a multiparametric MR examination of the prostate. However, within the variety of different acquisition methods, protocols, magnetic field strengths and multiparametric techniques that are used, consensus guidelines on dedicated MR protocols for specific clinical indications are lacking.

Suggested minimal requirements for a multiparametric MR imaging protocol for clinical evaluation of prostate cancer are T1- and T2-weighted MR imaging in combination with DW and dynamic contrast-enhanced MR imaging. T1- and T2-weighted MR imaging should be used for evaluation of anatomy. Dynamic contrast-enhanced MR imaging can be used for high-sensitivity identification of potential prostate cancer locations. Unfortunately, little standardization in dynamic contrast-enhanced MR acquisition and analysis exists. DW imaging or MR spectroscopic imaging are accurate functional MR techniques, and they may be added to improve specificity for different clinical indications. DW imaging is the most practical and simple accurate functional imaging technique; however, it is prone to motion and susceptibility artifacts. MR spectroscopic imaging is an accurate technique that, like DW imaging, can be used for assessing prostate cancer aggressiveness. Expertise and longer imaging times are prerequisites for MR spectroscopic imaging, which may ultimately decrease its clinical applicability.

Because the reported accuracies of multiparametric MR imaging techniques for different indications are inconsistent, definitive conclusions on the accuracies of (combined) multiparametric MR imaging techniques for a particular clinical prostate cancer problem are difficult to make. In general, the addition of functional MR techniques to T2-weighted MR imaging improves accuracy for both localization and local staging of prostate cancer in comparison to the accuracy of T2-weighted MR imaging alone. Of all clinical indications for multiparametric MR imaging of the prostate, localization is the most important. Accurate determination of prostate cancer location(s) results in more accurate prostate cancer staging and MR guidance of prostate biopsy and therapy.

Currently, multiparametric MR imaging is performed at only a limited number of centers worldwide. Development of expertise in functional MR
techniques and increased availability of equipment are needed, so that multiparametric prostate MR imaging can become a more accessible examination. To warrant accurate future multiparametric MR imaging prostate cancer diagnostics, computer programs are needed to support clinicians by allowing simple postprocessing and fast evaluation of the data.

Acknowledgment: The authors thank Yvonne Hoogveen, PhD, for editing the manuscript.

Acknowledgment: The authors thank Yvonne Hoogveen, PhD, for editing the manuscript.

Disclosures of Potential Conflicts of Interest: C.A.H. No potential conflicts of interest to disclose. J.O.B. No potential conflicts of interest to disclose. T.H. No potential conflicts of interest to disclose. D.Y. No potential conflicts of interest to disclose. D.M.S. No potential conflicts of interest to disclose. T.W.L.S. Financial activities related to the present article: none to disclose. Financial activity not related to the present article: received a grant or has grants pending from Siemens Healthcare. Other relationships: none to disclose. P.C.V. No potential conflicts of interest to disclose. H.H. No potential conflicts of interest to disclose. L.M.v.O. No potential conflicts of interest to disclose. J.A.W. No potential conflicts of interest to disclose. A.H. Financial activities related to the present article: Institution has received funds for consultancy for Siemens Healthcare. Other relationships: none to disclose. J.J.F. Financial activities related to the present article: Received a grant or has grants pending from Siemens Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose.

References


64. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a
cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2011 Apr 22. [Epub ahead of print]


129. Giles SL, Morgan VA, Riches SF, Thomas K, Parker C, deSouza NM. Apparent diffusion coefficient as a predictive biomarker of prostate cancer progression: value of


